Q3 FY2026 · ended Sep 30, 2026 · Revenue $0 · Filed Oct 29, 2026
Viking Therapeutics, Inc. (VKTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $183.2 million. As of Sep 30, 2026 it held $959.8 million in cash and investments and $4.0 million in total debt.
Revenue
$0
Net income
$-183.19M
-101.8% vs year-ago quarter
Operating cash flow
$-138.19M
-47.0% vs year-ago quarter
Free cash flow
—
EPS
$-1.55
-91.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
127.52M
+12.8% vs year-ago quarter
Net cash
$955.77M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VKTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1607678
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$187.1M | -$132.6M | -$164.1M | -$164.7M | -$98.6M |
| Net income | -$183.2M | -$128.0M | -$158.3M | -$157.7M | -$90.8M |
| Diluted EPS | -$1.55 | -$1.10 | -$1.37 | -$1.38 | -$0.81 |
| Operating cash flow | -$138.2M | -$125.2M | -$114.0M | -$85.3M | -$94.0M |
| Total assets | $977.2M | $521.9M | $608.2M | $715.7M | $739.4M |
| Total liabilities | $388.6M | $113.6M | $106.3M | $76.7M | $26.4M |
| Stockholders' equity | $588.6M | $408.3M | $501.9M | $639.1M | $713.0M |
| Cash and investments | $959.8M | $501.7M | $603.0M | $705.7M | $714.6M |
| Total debt | $4.0M | $4.1M | $0 | $137,000 | $755,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 28, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
All 652 Viking Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.